Menu
Not yet recruiting NCT07362082

A Clinical Trial of Telehealth Treatment for Opioid Use Disorders

No phase Interventional Opioid Use Disorder

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: RecoveryPad platform.
Who it may be relevant to
Registry conditions: Opioid Use Disorder. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Randomized Clinical Trial of Telehealth Treatment for Opioid Use Disorders

Overview

This trial will assess effects of enrollment in a comprehensive telehealth platform, RecoveryPad (RP), in adults with moderate or severe opioid use disorder.

Interventions

  • Device RecoveryPad platform
    Telehealth platform to enhance motivation and engagement in treatment for OUD

Primary outcome measures

  • Attendance for MOUD [Time frame: Up to 30 days]
Secondary outcome measures (4)
  • Attendance for MOUD [Time frame: Up to 90 days]
  • Engagement with MOUD [Time frame: Up to 90 days]
  • Overdose Events at 30 Days [Time frame: Up to 30 days]
  • Overdose Events at 90 Days [Time frame: Up to 90 days]

Eligibility criteria

Inclusion criteria

  • Can speak, read and write in English
  • Provision of signed and dated informed consent form
  • Screened positive for OUD, moderate or severe, based on the Diagnostic and Statistical Manual-5th Edition
  • Have a working cell phone number and working device that can access a web browser and receive texts (i.e., smartphone, tablet or computer)
  • Can provide a working email address OR be willing to create one

Exclusion criteria

  • Current use of buprenorphine, methadone, or naltrexone for a substance use disorder
  • Pregnancy
  • Known current suicide risk based on participant self-report
  • On parole or incarcerated at time of enrollment based on participant self-report

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 1 center
  • Yale University — New Haven

Identifiers

NCT: NCT07362082 · 2000042683 · 4R33DA057675-02 · 1R61DA057675-01 · 2000041129

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗